Comparison of the Acute Hematopoietic Capacities of Erythropoietin and U-74389G Concerning Hematocrit Levels.
This study compared the hematopoietic capacities of erythropoietin (Epo) and antioxidant drug U-74389G, based on 2 preliminary studies. The provided results on hematocrit levels augmentation were co-evaluated in a hypoxia reoxygenation protocol of an animal model.



Hematocrit levels were evaluated at the 60th reoxygenation min (for groups A, C and E) and at the 120th reoxygenation min (for groups B, D and F) in 60 rats. Groups A and B received no drugs, rats from groups C and D were administered with Epo; whereas rats from groups E and F were administered with U-74389G.



The first preliminary study of Epo non-significantly increased the hematocrit levels by 0.24%+1.38% (p-value=0.8586). The second preliminary study of U-74389G significantly raised the hematocrit levels by 3.16%+1.33% (p-value=0.0196). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that U-74389G has approximately 12.66-fold higher hematopoietic potency than Epo (p-value=0.0000).



The anti-oxidant capacities of U-74389G provide satisfactory acute hematopoietic properties; presenting approximately 12.66-fold hematocrit level rise than epo (p-value=0.0000).
Department of Obstetrics & Gynecology, Mesologi County Hospital, Nafpaktou Street, Mesologi 30200, Etoloakarnania. Greece.
Constantinos
C
Tsompos
Department of Obstetrics & Gynecology, Aretaieion Hospital, Athens University, Attiki. Greece.
Constantinos
C
Panoulis
Department of Surgery, Ippokrateion General Hospital, Athens University, Attiki. Greece.
Konstantinos
K
Toutouzas
Department of Biologic Chemistry, Athens University, Attiki. Greece.
Aggeliki
A
Triantafyllou
Department of Surgery, Ippokrateion General Hospital, Athens University, Attiki. Greece.
George
G
Zografos
Experimental Research Centre ELPEN Pharmaceuticals, S.A. Inc., Co., Attiki. Greece.
Apostolos
A
Papalois
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004921:Erythropoietin / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D000860:Hypoxia / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D011281:Pregnatrienes / Q000494:pharmacology / Q000627:therapeutic use*; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000097:blood / Q000150:complications / Q000188:drug therapy*
D000975:Antioxidants; D011281:Pregnatrienes; D004921:Erythropoietin; C074965:U 74389F
Hypoxia; U-74389G; cytokine; erythropoietin; hematocrit levels; reoxygenation